Tauns Laboratories (TSE:197A) Current Deferred Revenue: 円0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:197A Tauns Laboratories Inc TSE:197A
14 GF Score
Price 円515.00
! 9 Warning Signs
View Full Analysis

What is Tauns Laboratories Current Deferred Revenue?

Tauns Laboratories TSE:197A +0.39% 14 Current Deferred Revenue is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:197A with a GF Score™ of 14/100. The stock has 9 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Tauns Laboratories's current deferred revenue for the quarter that ended in Mar. 2026 was 円0 Mil.

Tauns Laboratories Current Deferred Revenue Related Terms

Tauns Laboratories Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Tauns Laboratories's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories Current Deferred Revenue Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Current Deferred Revenue
132.14 19.81 9.89 78.61 42.01

Tauns Laboratories Quarterly Data
Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial 78.61 0.00 0.00 0.00 42.01
TSE:197A
14GF Score
Tauns Laboratories Inc TSE:197A
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of 円0 Mil mean?
Tauns Laboratories (TSE:197A) has a Current Deferred Revenue of 円0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Tauns Laboratories and its competitors.
Is Tauns Laboratories' Current Deferred Revenue too high?
Tauns Laboratories' current Current Deferred Revenue is 円0 Mil. Overall, Tauns Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Current Deferred Revenue compare to ISRG and BDX?
Tauns Laboratories' Current Deferred Revenue of 円0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Tauns Laboratories and its competitors. Tauns Laboratories's current Current Deferred Revenue is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Current Deferred Revenue of 円0 Mil. The current Current Deferred Revenue is 円0 Mil. Tauns Laboratories' overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Current Deferred Revenue is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tauns Laboratories Business Description

Address 761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
14GF Score

Get the complete analysis for TSE:197A

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円515.00
Price